I am a
Home I AM A Search Login

Papers of the Week


Papers: 18 Feb 2023 - 24 Feb 2023

RESEARCH TYPE:
Clinical


Human Studies, Molecular/Cellular, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2023 Mar


Lancet Neurol


36804093


22


3

Editor's Pick

Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.

Authors

Lipton RB, Croop R, Stock DA, Madonia J, Forshaw M, Lovegren M, Mosher L, Coric V, Goadsby PJ

Abstract

Intranasal formulations can provide treatment options for people with migraine in whom oral drugs are ineffective, slow-acting, or intolerable because of nausea and vomiting. Zavegepant, an intranasally administered small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, was previously assessed in a phase 2/3 trial. This phase 3 trial aimed to compare the efficacy, tolerability, safety, and timecourse of response for zavegepant nasal spray with placebo in the acute treatment of migraine.